Breakthrough in Psoriasis Treatment Biologics and Small Molecule Therapies Take CenterStage

银屑病治疗新突破！生物制剂与小分子靶向药最新梳理 – 信息提炼

This article provides a comprehensive overview ofthe latest advancements in psoriasis treatment, focusing on the emergence of biologics and small molecule targeted therapies. Here’s a breakdown of the key information:

1. Psoriasis: A Growing Global Concern

Psoriasis, commonly known as 牛皮癣 in China, affects over 650million people worldwide, with a prevalence of 0.47% in China.
It’s a chronic, relapsing, inflammatory, and systemic disease triggered by a complex interplay of genetic, immune, and environmental factors.
The Th17/IL-17 pathway plays a crucial role in its pathogenesis, making IL-17, IL-23, and TNF-α key therapeutic targets.

2. Biologics: ANew Era of Targeted Therapy

Biologics have revolutionized psoriasis treatment by targeting specific cytokines and receptors, leading to significant improvements in efficacy and quality of life for patients.
The first generation of biologics focused on TNF-α inhibition, achieving PASI 75 response rates, surpassing traditional therapies.
The second generation targets multiple pathways, including IL-12, IL-17, and IL-23, offering even more tailored treatment options.
Currently, 78 biologics are approved globally for psoriasis, with 31 available in China.
Several promising biologics are inthe pipeline, including Hengrui’s Funaquizumab, which received approval in August 2024, and biosimilars of ustekinumab and adalimumab.

3. Small Molecule Targeted Therapies: A Complementary Approach

While biologics have proven successful, their large molecularsize limits their ability to penetrate cells.
Small molecule drugs targeting intracellular signaling pathways involved in inflammation are emerging as a complementary treatment strategy.
These drugs target various pathways, including PDE4, JAK-STAT, S1P receptors, and ROR, offering alternative treatment options.
Several small molecule drugsare already approved for psoriasis, including apremilast, roflumilast, deucravacitinib, tofacitinib, and upadacitinib.
Numerous novel small molecule drugs are in clinical trials, showcasing promising results in Phase II studies.

4. Domestic Innovation in China: A Growing Force

China is actively developing its own psoriasis treatment pipeline, with over 50 domestic innovative drugs in clinical development.
These drugs target various pathways, with TYK2, JAK1, IL-17A, and IL-17 being the most common targets.
*The majority of these drugs are chemical entities, highlighting the focus on small molecule therapies.

5. Future Outlook: A Brighter Horizon for Psoriasis Patients

The rapid advancement of both biologics and small molecule targeted therapies is transforming psoriasis treatment.
Patients are benefiting from more effective and personalized treatment options, leading to improved quality of life.
Continued innovation and research promise even more effective and convenient treatments in the future, offering hope for a brighter future for psoriasis patients.

Key Takeaways:

Psoriasis treatment is undergoing a significant transformation with the emergence of targeted therapies.
Biologics and smallmolecule drugs are offering patients more effective and personalized treatment options.
Domestic innovation in China is contributing to the development of novel psoriasis therapies.
The future holds great promise for psoriasis patients with ongoing research and development of even more effective and convenient treatment options.

Further Information Needed:

Specific details on theclinical trials for the promising biologics and small molecule drugs mentioned in the article.
Information on the cost and accessibility of these new therapies in China.
Insights into the regulatory landscape for psoriasis treatments in China.
A comparison of the efficacy and safety profiles of different biologics and small molecule drugs.

This information will help to provide a more comprehensive and informative report on the latest breakthroughs in psoriasis treatment.